vs
UNITIL CORP（UTL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
UNITIL CORP的季度营收约是再鼎医药的1.3倍（$161.5M vs $127.1M），UNITIL CORP同比增速更快（26.7% vs 17.1%），再鼎医药自由现金流更多（$-26.7M vs $-36.3M），过去两年再鼎医药的营收复合增速更高（20.8% vs -4.9%）
Unitil是一家跨州电力与天然气公用事业公司，业务覆盖美国新罕布什尔州、马萨诸塞州与缅因州。公司最早前身是1849年在缅因州成立的波特兰煤气灯公司，现企业主体于1984年设立，总部位于新罕布什尔州。目前公司总市值约6.8651亿美元，为约10.24万电力客户、超7.59万天然气客户提供服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
UTL vs ZLAB — 直观对比
营收规模更大
UTL
是对方的1.3倍
$127.1M
营收增速更快
UTL
高出9.5%
17.1%
自由现金流更多
ZLAB
多$9.6M
$-36.3M
两年增速更快
ZLAB
近两年复合增速
-4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $161.5M | $127.1M |
| 净利润 | $19.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 21.5% | -54.6% |
| 净利率 | 11.8% | — |
| 营收同比 | 26.7% | 17.1% |
| 净利润同比 | 21.8% | — |
| 每股收益（稀释后） | $1.05 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收UTLZLAB
| Q4 25 | $161.5M | $127.1M | ||
| Q3 25 | $101.1M | $115.4M | ||
| Q2 25 | $102.6M | $109.1M | ||
| Q1 25 | $170.8M | $105.7M | ||
| Q4 24 | $127.5M | $108.5M | ||
| Q3 24 | $92.9M | $101.8M | ||
| Q2 24 | $95.7M | $100.1M | ||
| Q1 24 | $178.7M | $87.1M |
净利润UTLZLAB
| Q4 25 | $19.0M | — | ||
| Q3 25 | $-300.0K | $-36.0M | ||
| Q2 25 | $4.0M | $-40.7M | ||
| Q1 25 | $27.5M | $-48.4M | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $0 | $-41.7M | ||
| Q2 24 | $4.3M | $-80.3M | ||
| Q1 24 | $27.2M | $-53.5M |
毛利率UTLZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率UTLZLAB
| Q4 25 | 21.5% | -54.6% | ||
| Q3 25 | 6.9% | -42.3% | ||
| Q2 25 | 13.0% | -50.3% | ||
| Q1 25 | 27.0% | -53.3% | ||
| Q4 24 | 22.1% | -62.6% | ||
| Q3 24 | 6.2% | -66.6% | ||
| Q2 24 | 13.0% | -76.0% | ||
| Q1 24 | 24.7% | -80.7% |
净利率UTLZLAB
| Q4 25 | 11.8% | — | ||
| Q3 25 | -0.3% | -31.2% | ||
| Q2 25 | 3.9% | -37.3% | ||
| Q1 25 | 16.1% | -45.8% | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | — | -40.9% | ||
| Q2 24 | 4.5% | -80.2% | ||
| Q1 24 | 15.2% | -61.4% |
每股收益（稀释后）UTLZLAB
| Q4 25 | $1.05 | $-0.05 | ||
| Q3 25 | $-0.02 | $-0.03 | ||
| Q2 25 | $0.25 | $-0.04 | ||
| Q1 25 | $1.69 | $-0.04 | ||
| Q4 24 | $0.97 | $-0.09 | ||
| Q3 24 | $0.00 | $-0.04 | ||
| Q2 24 | $0.27 | $-0.08 | ||
| Q1 24 | $1.69 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.6M | $689.6M |
| 总债务越低越好 | $670.5M | — |
| 股东权益账面价值 | $609.6M | $715.5M |
| 总资产 | $2.1B | $1.2B |
| 负债/权益比越低杠杆越低 | 1.10× | — |
8季度趋势，按日历期对齐
现金及短期投资UTLZLAB
| Q4 25 | $15.6M | $689.6M | ||
| Q3 25 | $14.6M | $717.2M | ||
| Q2 25 | $8.5M | $732.2M | ||
| Q1 25 | $10.2M | $757.3M | ||
| Q4 24 | $6.3M | $779.7M | ||
| Q3 24 | $6.3M | $616.1M | ||
| Q2 24 | $2.8M | $630.0M | ||
| Q1 24 | $6.3M | $650.8M |
总债务UTLZLAB
| Q4 25 | $670.5M | — | ||
| Q3 25 | $670.5M | — | ||
| Q2 25 | $640.7M | — | ||
| Q1 25 | $642.1M | — | ||
| Q4 24 | $643.3M | — | ||
| Q3 24 | $643.3M | — | ||
| Q2 24 | $511.3M | — | ||
| Q1 24 | $512.8M | — |
股东权益UTLZLAB
| Q4 25 | $609.6M | $715.5M | ||
| Q3 25 | $597.2M | $759.9M | ||
| Q2 25 | $532.8M | $791.7M | ||
| Q1 25 | $534.1M | $810.8M | ||
| Q4 24 | $512.5M | $840.9M | ||
| Q3 24 | $502.4M | $667.7M | ||
| Q2 24 | $508.8M | $704.2M | ||
| Q1 24 | $510.8M | $762.2M |
总资产UTLZLAB
| Q4 25 | $2.1B | $1.2B | ||
| Q3 25 | $1.9B | $1.2B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $1.8B | $1.2B | ||
| Q3 24 | $1.7B | $985.3M | ||
| Q2 24 | $1.7B | $987.4M | ||
| Q1 24 | $1.7B | $988.4M |
负债/权益比UTLZLAB
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.12× | — | ||
| Q2 25 | 1.20× | — | ||
| Q1 25 | 1.20× | — | ||
| Q4 24 | 1.26× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-36.3M | $-26.7M |
| 自由现金流率自由现金流/营收 | -22.5% | -21.0% |
| 资本支出强度资本支出/营收 | 35.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.13× | — |
| 过去12个月自由现金流最近4个季度 | $-53.8M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流UTLZLAB
| Q4 25 | $21.4M | $-26.0M | ||
| Q3 25 | $15.6M | $-32.0M | ||
| Q2 25 | $42.2M | $-31.0M | ||
| Q1 25 | $52.1M | $-61.7M | ||
| Q4 24 | $23.3M | $-55.8M | ||
| Q3 24 | $26.1M | $-26.8M | ||
| Q2 24 | $49.9M | $-42.2M | ||
| Q1 24 | $26.6M | $-90.1M |
自由现金流UTLZLAB
| Q4 25 | $-36.3M | $-26.7M | ||
| Q3 25 | $-39.0M | $-35.0M | ||
| Q2 25 | $2.0M | $-33.9M | ||
| Q1 25 | $19.5M | $-63.2M | ||
| Q4 24 | $-32.3M | $-58.4M | ||
| Q3 24 | $-31.3M | $-28.2M | ||
| Q2 24 | $13.2M | $-42.9M | ||
| Q1 24 | $6.4M | $-91.1M |
自由现金流率UTLZLAB
| Q4 25 | -22.5% | -21.0% | ||
| Q3 25 | -38.6% | -30.4% | ||
| Q2 25 | 1.9% | -31.1% | ||
| Q1 25 | 11.4% | -59.9% | ||
| Q4 24 | -25.3% | -53.8% | ||
| Q3 24 | -33.7% | -27.7% | ||
| Q2 24 | 13.8% | -42.9% | ||
| Q1 24 | 3.6% | -104.5% |
资本支出强度UTLZLAB
| Q4 25 | 35.7% | 0.5% | ||
| Q3 25 | 54.0% | 2.6% | ||
| Q2 25 | 39.2% | 2.6% | ||
| Q1 25 | 19.1% | 1.5% | ||
| Q4 24 | 43.6% | 2.4% | ||
| Q3 24 | 61.8% | 1.3% | ||
| Q2 24 | 38.3% | 0.7% | ||
| Q1 24 | 11.3% | 1.1% |
现金转化率UTLZLAB
| Q4 25 | 1.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 10.55× | — | ||
| Q1 25 | 1.89× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 11.60× | — | ||
| Q1 24 | 0.98× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
UTL
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
